NCT02737891
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
See it on ClinicalTrials.gov ↗60 people
35%
65%
21 womenmiddle line = equal numbers39 men
- Phase
- PHASE2
- Paid for by
- Saniona
- Finished
- 2017-03
- Health conditions
- Type 2 Diabetes Mellitus
- Who could join
- Anyone
- Ages
- 18 Years – 70 Years
- Average age
- mean 64 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Heart failure class II or greater according to the New York Heart Association (NYHA) or decompensated heart failure”
- No diabetes
Women with diabetes were turned away.
“Treatment with insulin and/or other injectable anti-diabetic medications, or TZDs”
Study titles and rules are shown in their original English.